Search results

Order by most recent / most popular / relevance

Results: 1-10 of 59

Pharma in brief - Canada: Federal Court dismisses prohibition application for drospirenone YASMIN due to non-infringing process

Norton Rose Canada LLP
-
Canada
-
June 15 2013

Bayer Inc. and Bayer Pharma Aktiengesellschaft (“Bayer”) brought an application pursuant to section 6 of the Patented Medicines (Notice of

USTR slams Canada over the treatment of pharmaceutical patents

Norton Rose Canada LLP
-
Canada
-
May 6 2013

On May 1, 2013, the United States Trade Representative (“USTR”) released its annual IP report for 2013. Canada has been placed on the “Watch List"

Patent for esomeprazole tablets found not to be obvious

Norton Rose Canada LLP
-
Canada
-
March 29 2013

AstraZeneca Canada Inc. and AstraZeneca AB (“AstraZeneca”) brought an application pursuant to section 6 of the Patented Medicines (Notice of

Federal court issues prohibition order in respect of zoledronate ACLASTA

Norton Rose Canada LLP
-
Canada
-
March 22 2013

Novartis Pharmaceuticals Canada Inc. (“Novartis”) brought an application pursuant to s. 6 of the Patented Medicines (Notice of Compliance) Regulations

Federal Court dismisses prohibition application for quetiapine tablets SEROQUEL XR

Norton Rose Canada LLP
-
Canada
-
March 20 2013

AstraZeneca Canada Inc. and AstraZeneca UK Limited (“AstraZeneca”) brought an application pursuant to section 6 of the Patented Medicines (Notice of

Federal Court upholds validity of patent for escitalopram (CIPRALEX)

Norton Rose Canada LLP
-
Canada
-
March 19 2013

Apotex Inc. (“Apotex”) brought an action for impeachment seeking a declaration that Lundbeck’s Canadian Patent No. 1,339,452 (the “’452 Patent”) is

Federal Court upholds validity of GLEEVEC patent

Norton Rose Canada LLP
-
Canada
-
February 26 2013

Teva Canada Limited (“Teva”) and Apotex Inc. (“Apotex”) wish to sell generic versions of GLEEVEC, a highly effective drug for the treatment of

Federal Court confirms that where NOA is withdrawn, PM(NOC) application for a Prohibition Order is moot

Norton Rose Canada LLP
-
Canada
-
January 28 2013

Eli Lilly Canada Inc. (“Lilly”) brought an application under the Patented Medicines (Notice of Compliance) Regulations (the “NOC Regulations”) for an

Federal Court of Appeal confirms that an enantiomer of a previously approved medicinal ingredient is not an “innovative drug”

Norton Rose Canada LLP
-
Canada
-
January 23 2013

This was an appeal from the decision of the Federal Court which had dismissed Takeda’s application for judicial review of the Minister’s refusal to

Ontario Superior Court affirms that section 8 damages do not include disgorgement of innovator’s profits

Norton Rose Canada LLP
-
Canada
-
January 22 2013

This is the first proceeding under the Patented Medicine (Notice of Compliance Regulations) (“NOC Regulations”) brought by Apotex Inc. in the Ontario

next >